SCHEMBL888069

SCHEMBL888069

CC(C)(C)OC(=O)OC(C(=O)OC(C)(C)C)[C@H]1O[C@@H](n2cnc3c(N)ncnc32)C[C@@H]1O

nearest known ligand 0.55

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.46
ENPP1 P22413 2/20 0.45
P2RY1 P47900 1/20 0.45
AHCY P23526 7/20 0.44
DOT1L Q8TEK3 1/20 0.43
STING1 Q86WV6 1/20 0.43
ADORA3 P0DMS8 1/20 0.42
HSP90B1 P14625 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL888256 0.81 STING1 (0.42) POLBENPP1P2RY1AHCYDOT1L
SCHEMBL5621212 0.78 AHCY (0.52) POLBENPP1P2RY1AHCYSTING1
SCHEMBL5621204 0.78 AHCY (0.52) POLBENPP1P2RY1AHCYSTING1
SCHEMBL2835834 0.78 POLB (0.45) POLBENPP1P2RY1AHCYSTING1
SCHEMBL718524 0.78 POLB (0.45) POLBENPP1P2RY1AHCYSTING1
SCHEMBL66046 0.77 AHCY (0.57) POLBENPP1P2RY1AHCYSTING1
SCHEMBL18952729 0.76 AHCY (0.52) POLBENPP1P2RY1AHCYSTING1
SCHEMBL7192496 0.76 AHCY (0.54) POLBENPP1P2RY1AHCYSTING1
SCHEMBL9875644 0.76 AHCY (0.56) POLBENPP1P2RY1AHCYSTING1
SCHEMBL9875640 0.76 AHCY (0.56) POLBENPP1P2RY1AHCYSTING1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3137477-A1 COMPOUNDS COMPOSITIONS AND METHODS INCLUDING THERMALLY LABILE MOIETIES Biosearch Technologies, Inc. (US) 2017-03-08 EP disclosed
EP-2125856-B1 PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING LASERGEN INC (US) 2016-09-14 EP disclosed
WO-2015167620-A1 COMPOUNDS COMPOSITIONS AND METHODS INCLUDING THERMALLY LABILE MOIETIES BIOSEARCH TECHNOLOGIES, INC. (US) 2015-11-05 WO disclosed
US-8969535-B2 Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing LASERGEN, INC. (US) 2015-03-03 US disclosed
US-20130072388-A1 PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN IN DNA SEQUENCING AGILENT TECHNOLOGIES, INC. 2013-03-21 US disclosed
US-8361727-B2 3′OH-unblocked, nucleotides and nucleosides base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing LASERGEN, INC. (US) 2013-01-29 US disclosed
US-20110287427-A1 3'OH-UNBLOCKED, NUCLEOTIDES AND NUCLEOSIDES BASE MODIFIED WITH LABELS AND PHOTOCLEAVABLE, TERMINATING GROUPS AND METHODS FOR THEIR USE IN DNA SEQUENCING LASERGEN, INC. (US) 2011-11-24 US disclosed
US-7964352-B2 3′-OH unblocked nucleotides and nucleosides, base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing LASERGEN, INC. (US) 2011-06-21 US disclosed
US-7897737-B2 Polymorphic identification; fluorescent dyes LASERGEN, INC. (US) 2011-03-01 US disclosed
EP-2125856-A2 PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING Lasergen, Inc. (US) 2009-12-02 EP disclosed
US-20090081686-A1 PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING AGILENT TECHNOLOGIES, INC. 2009-03-26 US disclosed
WO-2008070749-A2 PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING LASERGEN, INC. (US) 2008-06-12 WO disclosed
US-20080132692-A1 Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing AGILENT TECHNOLOGIES, INC. 2008-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132692-A1 Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing UNG, DCLRE1B, NT5C3B POLB 28/4885ENPP1 170/4885P2RY1 873/4885
US-20130072388-A1 PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN IN DNA SEQUENCING UNG, NT5C3B, OGG1 POLB 29/4885ENPP1 154/4885P2RY1 793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.